<b>SECURITIES</b>	AND EXCHANGE (	COMMISSION
	Washington, D.C. 20549	
	FORM 8-K	
	CURRENT REPORT	
Pursuant to Section	a 13 or 15(d) of The Securities E	xchange Act of 1934
Date of Repo	ort (Date of earliest event reported): Oo	ctober 3, 2004
SYNBI	OTICS CORPOR	ATION
(Ex	act name of registrant as specified in its cha	rter)
	Commission file number 0-11303	
California (State or other jurisdiction		95-3737816 (I.R.S. Employer
of incorporation )		Identification No.)
11011 Via Frontera		
San Diego, California		92127

(Address of principal executive offices)

1

(Zip Code)

# Edgar Filing: SYNBIOTICS CORP - Form 8-K

Registrant s telephone number, including area code: (858) 451-3771

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- " Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- " Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- " Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- "Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

# Edgar Filing: SYNBIOTICS CORP - Form 8-K

## Item 3.02. Unregistered Sales of Equity Securities.

On October 3, 2004, we entered into a Series C Purchase Agreement (the Series C Agreement ) with Franklin Kling. Under the Series C Agreement we sold to Mr. Kling 50 newly-issued shares of unregistered Series C Preferred Stock for \$50,000 in cash. Each share of Series C Preferred Stock is convertible at any time into 7,785 unregistered shares of our common stock (subject to anti-dilution adjustments). This transaction was a Section 4(2) private offering, involving no underwriters.

#### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

## SYNBIOTICS CORPORATION

Date: October 7, 2004

/s/ Keith A. Butler

Keith A. Butler Vice President - Finance and Chief Financial Officer

-1-